The Tamesis
Asia Pacific is expected to be the fastest growing market.
The global next-generation sequencing (NGS) market is expected to grow from US$1.494 billion in 2025 to US$2.953 billion in 2030, representing a compound annual growth rate of 14.6%, according to a new report from MarketsandMarkets.
Rising government funding for sequencing projects, increasing use of NGS in chronic diseases, and expanding use in clinical diagnostics are driving market growth.
Advances in bioinformatics and data analytics also play a key role, allowing faster processing of sequencing data and extraction of actionable insights.
At the same time, declining sequencing costs are expanding access to applications in personalized medicine, genomic research, and large-scale population genomics initiatives.
Integrating artificial intelligence and machine learning into sequencing workflows further improves efficiency and accuracy, accelerating innovation in the field.
In terms of product range, the product segment leads the market, supported by recurring revenue from consumables and high-priced instruments, while services remains the second largest segment.
Sequencing by synthesis dominates the platform technology, followed by ion semiconductor sequencing. Sequencing services are the largest service type, with bioinformatics and data analysis services in second place.
Diagnostics is the leading application, driven by routine clinical use and large-scale screening programs, with academic and research institutions being the largest end users, employing advanced technologies such as single-cell sequencing and spatial transcriptomics.
Asia Pacific is expected to be the fastest growing market, driven by infrastructure development, population genomics initiatives, and collaborations among pharmaceutical and biotech companies.
